Literature DB >> 15499630

High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.

Alejo A Morales1, Anna Olsson, Fredrik Celsing, Anders Osterborg, Mikael Jondal, Lyda M Osorio.   

Abstract

In order to identify regulatory genes involved in the development of an apoptosis-resistant phenotype in patients with chemotherapy refractory B-cell chronic lymphocytic leukemia (B-CLL) expression of apoptosis-regulating genes in B-CLL cells was quantified using cDNA arrays and RT-PCR. Data were obtained from and compared between 2 groups of B-CLL patients with either nonprogressive, indolent, previously untreated disease and with leukemic cells sensitive to in vitro fludarabine-induced apoptosis, referred to as sensitive B-CLL (sB-CLL) or with progressive, chemotherapy refractory disease and with leukemic cells resistant to in vitro fludarabine-induced apoptosis, referred to as resistant B-CLL (rB-CLL). By performing a supervised clustering of genes that most strongly discriminated between rB-CLL vs. sB-CLL a small group of genes was identified, where bfl-1 was the strongest discriminating gene (p < 0.05), with higher expression in rB-CLL. A group of apoptosis-regulating genes were modulated during induction of apoptosis by serum deprivation in vitro in a similar manner in all cases studied. However, bfl-1 was preferentially downregulated in sB-CLL as compared to rB-CLL (p < 0.05). We conclude that bfl-1 may be an important regulator of B-CLL apoptosis, which could contribute to disease progression and resistance to chemotherapy, and as such represent a future potential therapeutic target. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15499630     DOI: 10.1002/ijc.20614

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

Review 1.  BCL2A1: the underdog in the BCL2 family.

Authors:  M Vogler
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

3.  The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells.

Authors:  Zachary L Pratt; Jingzhu Zhang; Bill Sugden
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 4.  Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

Authors:  Cristina Correia; Sun-Hee Lee; X Wei Meng; Nicole D Vincelette; Katherine L B Knorr; Husheng Ding; Grzegorz S Nowakowski; Haiming Dai; Scott H Kaufmann
Journal:  Biochim Biophys Acta       Date:  2015-03-27

5.  Kruppel-like factor 7 overexpression suppresses hematopoietic stem and progenitor cell function.

Authors:  Laura G Schuettpelz; Priya K Gopalan; Felipe O Giuste; Molly P Romine; Ronald van Os; Daniel C Link
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

6.  Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.

Authors:  Gaofeng Fan; Matthew J Simmons; Sheng Ge; Jui Dutta-Simmons; Jérôme Kucharczak; Yacov Ron; David Weissmann; Chiann-Chyi Chen; Chandreyee Mukherjee; Eileen White; Céline Gélinas
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

7.  Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells.

Authors:  Héloïse Macaire; Aurélien Riquet; Vincent Moncollin; Marie-Claude Biémont-Trescol; Madeleine Duc Dodon; Olivier Hermine; Anne-Laure Debaud; Renaud Mahieux; Jean-Michel Mesnard; Marlène Pierre; Louis Gazzolo; Nathalie Bonnefoy; Hélène Valentin
Journal:  J Biol Chem       Date:  2012-05-02       Impact factor: 5.157

8.  ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.

Authors:  S H Tonino; J van Laar; M H van Oers; J Y Wang; E Eldering; A P Kater
Journal:  Oncogene       Date:  2010-10-11       Impact factor: 9.867

9.  TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1.

Authors:  Loïc Lionnard; Pauline Duc; Margs S Brennan; Andrew J Kueh; Martin Pal; Francesca Guardia; Barbara Mojsa; Maria-Alessandra Damiano; Stéphan Mora; Iréna Lassot; Ramya Ravichandran; Claude Cochet; Abdel Aouacheria; Patrick Ryan Potts; Marco J Herold; Solange Desagher; Jérôme Kucharczak
Journal:  Cell Death Differ       Date:  2018-07-24       Impact factor: 15.828

10.  Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering.

Authors:  Edward P Harvey; Zachary J Hauseman; Daniel T Cohen; T Justin Rettenmaier; Susan Lee; Annissa J Huhn; Thomas E Wales; Hyuk-Soo Seo; James Luccarelli; Catherine E Newman; Rachel M Guerra; Gregory H Bird; Sirano Dhe-Paganon; John R Engen; James A Wells; Loren D Walensky
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.